Search

Research

Myeloperoxidase is released by neutrophils in inflamed tissues. MPO oxidizes chloride, bromide, and thiocyanate to produce hypochlorous acid, hypobromous acid, and hypothiocyanous acid, respectively. These oxidants are toxic to pathogens, but may also react with host cells to elicit biological activity and potential toxicity. In cystic fibrosis and related diseases, increased neutrophil inflammation leads to increased airway MPO and airway epithelial cell exposure to its oxidants.

The Respiratory Physiology Platform at the Wal-yan Respiratory Research Centre offers access to specialist equipment housed within the outpatient research department at Perth Children’s Hospital, dedicated for research use.

The Kids Research Institute Australia, Perth Children’s Hospital Foundation and Perth Children’s Hospital have formed a strategic partnership to support the establishment and operation of the Wal-yan Respiratory Research Centre.

On average, a person can expect to take more than 700 million breaths in their lifetime.

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

Respiratory disease is a global issue and international networks are critical to informing best-practice approaches to the clinical care and management of childhood respiratory health.

Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.

News & Events

A bold respiratory research project will investigate whether wearable devices could drastically change clinical care for children living with chronic diseases such as cystic fibrosis. 

News & Events

Wal-yan Respiratory Research Centre PhD student Niamh Troy has found how OM85 helps babies fight off severe lung infections.

News & Events

Natasha, who is a participant in the West Australian Lung Health in Prematurity (WALHIP) study, this week became the first person to receive a lung health assessment using new state-of-the-art lung function testing equipment at Perth Children’s Hospital.